The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries.
BACKGROUND:With approximately 3 billion people at risk of acquiring the infection, dengue fever is now considered the most important mosquito-borne viral disease in the world, with 390 million dengue infections occurring every year, of which 96 million manifest symptoms with any level of disease sev...
Published in: | PLOS Neglected Tropical Diseases |
---|---|
Main Authors: | , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016
|
Subjects: | |
Online Access: | https://doi.org/10.1371/journal.pntd.0005179 https://doaj.org/article/4273ff1f67554d19a02462a26f692540 |
id |
ftdoajarticles:oai:doaj.org/article:4273ff1f67554d19a02462a26f692540 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:4273ff1f67554d19a02462a26f692540 2023-05-15T15:12:42+02:00 The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. Maíra Aguiar Nico Stollenwerk Scott B Halstead 2016-12-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0005179 https://doaj.org/article/4273ff1f67554d19a02462a26f692540 EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC5176165?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0005179 https://doaj.org/article/4273ff1f67554d19a02462a26f692540 PLoS Neglected Tropical Diseases, Vol 10, Iss 12, p e0005179 (2016) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2016 ftdoajarticles https://doi.org/10.1371/journal.pntd.0005179 2022-12-31T13:31:39Z BACKGROUND:With approximately 3 billion people at risk of acquiring the infection, dengue fever is now considered the most important mosquito-borne viral disease in the world, with 390 million dengue infections occurring every year, of which 96 million manifest symptoms with any level of disease severity. Treatment of uncomplicated dengue cases is only supportive and severe dengue cases require hospital intensive care. A vaccine now licensed in several countries and developed by Sanofi Pasteur (CYD-TDV, named Dengvaxia), was able to protect, in the first 25 months of the two Phase III, 66% of a subset of 9-16 year old participants. However, a significantly lower efficacy (including negative vaccine efficacy) was noted for children younger than 9 years of age. METHODOLOGY/PRINCIPAL FINDINGS:Analysis of year 3 results of phase III trials of Dengvaxia suggest high rates of protection of vaccinated partial dengue immunes but high rates of hospitalizations during breakthrough dengue infections of persons who were vaccinated when seronegative, with vaccine appearing to induce enhancing antibodies (ADE). An age structured model was developed based on Sanofi's recommendation to vaccinate persons age 945 years in dengue endemic countries. The model was used to explore the clinical burden of two vaccination strategies: 1) Vaccinate 4 or 20% of individuals, ages 9-45 years, seropositives and seronegatives, and 2) vaccinate 4 or 20% of individuals, ages 9-45 years, who are dengue immune only. CONCLUSIONS/SIGNIFICANCE:Our results show that vaccinating dengue monotypic immune individuals prevents dengue hospitalizations, but at the same time dengue infections of vaccine-sensitized persons increases hospitalizations. When the vaccine is given only to partial immune individuals, after immunological screening of the population, disease burden decreases considerably. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Pasteur ENVELOPE(140.099,140.099,-66.625,-66.625) PLOS Neglected Tropical Diseases 10 12 e0005179 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Maíra Aguiar Nico Stollenwerk Scott B Halstead The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
BACKGROUND:With approximately 3 billion people at risk of acquiring the infection, dengue fever is now considered the most important mosquito-borne viral disease in the world, with 390 million dengue infections occurring every year, of which 96 million manifest symptoms with any level of disease severity. Treatment of uncomplicated dengue cases is only supportive and severe dengue cases require hospital intensive care. A vaccine now licensed in several countries and developed by Sanofi Pasteur (CYD-TDV, named Dengvaxia), was able to protect, in the first 25 months of the two Phase III, 66% of a subset of 9-16 year old participants. However, a significantly lower efficacy (including negative vaccine efficacy) was noted for children younger than 9 years of age. METHODOLOGY/PRINCIPAL FINDINGS:Analysis of year 3 results of phase III trials of Dengvaxia suggest high rates of protection of vaccinated partial dengue immunes but high rates of hospitalizations during breakthrough dengue infections of persons who were vaccinated when seronegative, with vaccine appearing to induce enhancing antibodies (ADE). An age structured model was developed based on Sanofi's recommendation to vaccinate persons age 945 years in dengue endemic countries. The model was used to explore the clinical burden of two vaccination strategies: 1) Vaccinate 4 or 20% of individuals, ages 9-45 years, seropositives and seronegatives, and 2) vaccinate 4 or 20% of individuals, ages 9-45 years, who are dengue immune only. CONCLUSIONS/SIGNIFICANCE:Our results show that vaccinating dengue monotypic immune individuals prevents dengue hospitalizations, but at the same time dengue infections of vaccine-sensitized persons increases hospitalizations. When the vaccine is given only to partial immune individuals, after immunological screening of the population, disease burden decreases considerably. |
format |
Article in Journal/Newspaper |
author |
Maíra Aguiar Nico Stollenwerk Scott B Halstead |
author_facet |
Maíra Aguiar Nico Stollenwerk Scott B Halstead |
author_sort |
Maíra Aguiar |
title |
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. |
title_short |
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. |
title_full |
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. |
title_fullStr |
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. |
title_full_unstemmed |
The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. |
title_sort |
impact of the newly licensed dengue vaccine in endemic countries. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2016 |
url |
https://doi.org/10.1371/journal.pntd.0005179 https://doaj.org/article/4273ff1f67554d19a02462a26f692540 |
long_lat |
ENVELOPE(140.099,140.099,-66.625,-66.625) |
geographic |
Arctic Pasteur |
geographic_facet |
Arctic Pasteur |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
PLoS Neglected Tropical Diseases, Vol 10, Iss 12, p e0005179 (2016) |
op_relation |
http://europepmc.org/articles/PMC5176165?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0005179 https://doaj.org/article/4273ff1f67554d19a02462a26f692540 |
op_doi |
https://doi.org/10.1371/journal.pntd.0005179 |
container_title |
PLOS Neglected Tropical Diseases |
container_volume |
10 |
container_issue |
12 |
container_start_page |
e0005179 |
_version_ |
1766343345914773504 |